8-K - Zenas BioPharma, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Zenas BioPharma, Inc. disclosed the approval of its Amended and Restated Short-Term Incentive Plan, effective January 1, 2026. This plan establishes a discretionary annual cash bonus program for eligible employees, linking potential payouts to company performance and individual achievement.

Key Takeaways

1The Board of Directors approved the Amended and Restated Short-Term Incentive Plan on February 10, 2026.

2The plan is effective as of January 1, 2026.

3It is an annual discretionary cash bonus plan for regular full- and part-time employees of the Company and its subsidiaries.

4Bonus eligibility and amounts are determined based on Company performance and individual achievement of goals.

5A participant must remain employed through the payment date, which is no later than March 15 following the applicable calendar year.

6Awards are subject to the Company's Policy for Recoupment of Incentive Compensation and any other clawback policy.

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February

Management Change

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 # Zenas BioPharma, Inc. Amended and Restated Short-Term Incentive Plan 104 Cover Pa

Exhibits Only

Exhibits (2)

10.1

EXHIBIT 10.1

8-K

FORM 8-K